{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:18:49Z","timestamp":1759335529399},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,29]]},"DOI":"10.7759\/cureus.70435","type":"journal-article","created":{"date-parts":[[2024,9,29]],"date-time":"2024-09-29T12:17:48Z","timestamp":1727612268000},"source":"Crossref","is-referenced-by-count":1,"title":["The Impact of Uric Acid-Lowering Therapy on the Progression of Non-dialysis Chronic Kidney Disease: A Prospective Cohort Study"],"prefix":"10.7759","author":[{"given":"Nghia N","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tan Ngoc H","family":"Mai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bao T","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thuy Diem T","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tam Thanh T","family":"Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","author":"GBD Chronic Kidney Disease Collaboration","year":"2020","unstructured":"GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020, 395:709-33. 10.1016\/S0140-6736(20)30045-3","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60687-X","article-title":"Chronic kidney disease: global dimension and perspectives","volume":"382","author":"Jha V","year":"2013","unstructured":"Jha V, Garcia-Garcia G, Iseki K, et al.. Chronic kidney disease: global dimension and perspectives. Lancet. 2013, 382:260-72. 10.1016\/S0140-6736(13)60687-X","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2016-000256","article-title":"Chronic kidney disease in low-income to middle-income countries: the case for increased screening","volume":"2","author":"George C","year":"2017","unstructured":"George C, Mogueo A, Okpechi I, Echouffo-Tcheugui JB, Kengne AP. Chronic kidney disease in low-income to middle-income countries: the case for increased screening. BMJ Glob Health. 2017, 2:e000256. 10.1136\/bmjgh-2016-000256","journal-title":"BMJ Glob Health"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2016.05.008","article-title":"The economic burden of chronic kidney disease and end-stage renal disease","volume":"36","author":"Wang V","year":"2016","unstructured":"Wang V, Vilme H, Maciejewski ML, Boulware LE. The economic burden of chronic kidney disease and end-stage renal disease. Semin Nephrol. 2016, 36:319-30. 10.1016\/j.semnephrol.2016.05.008","journal-title":"Semin Nephrol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2013.02.369","article-title":"Association between depression and death in people with CKD: a meta-analysis of cohort studies","volume":"62","author":"Palmer SC","year":"2013","unstructured":"Palmer SC, Vecchio M, Craig JC, et al.. Association between depression and death in people with CKD: a meta-analysis of cohort studies. Am J Kidney Dis. 2013, 62:493-505. 10.1053\/j.ajkd.2013.02.369","journal-title":"Am J Kidney Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2017.05.001","article-title":"Asymptomatic hyperuricemia and chronic kidney disease: narrative review of a treatment controversial","volume":"8","author":"Eleftheriadis T","year":"2017","unstructured":"Eleftheriadis T, Golphinopoulos S, Pissas G, Stefanidis I. Asymptomatic hyperuricemia and chronic kidney disease: narrative review of a treatment controversial. J Adv Res. 2017, 8:555-60. 10.1016\/j.jare.2017.05.001","journal-title":"J Adv Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0190985","article-title":"Chronic kidney disease associated with decreased bone mineral density, uric acid and metabolic syndrome","volume":"13","author":"Pan BL","year":"2018","unstructured":"Pan BL, Loke SS. Chronic kidney disease associated with decreased bone mineral density, uric acid and metabolic syndrome. PLoS One. 2018, 13:e0190985. 10.1371\/journal.pone.0190985","journal-title":"PLoS One"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/s0009-8981(00)00359-4","article-title":"Uric acid calculi: types, etiology and mechanisms of formation","volume":"302","author":"Grases F","year":"2000","unstructured":"Grases F, Villacampa AI, Costa-Bauz\u00e1 A, S\u00f6hnel O. Uric acid calculi: types, etiology and mechanisms of formation. Clin Chim Acta. 2000, 302:89-104. 10.1016\/s0009-8981(00)00359-4","journal-title":"Clin Chim Acta"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-51010-6","article-title":"Nonlinearity association between hyperuricemia and all-cause mortality in patients with chronic kidney disease","volume":"14","author":"Liu YF","year":"2024","unstructured":"Liu YF, Han L, Geng YH, Wang HH, Yan JH, Tu SH. Nonlinearity association between hyperuricemia and all-cause mortality in patients with chronic kidney disease. Sci Rep. 2024, 14:673. 10.1038\/s41598-023-51010-6","journal-title":"Sci Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.01580210","article-title":"Effect of allopurinol in chronic kidney disease progression and cardiovascular risk","volume":"5","author":"Goicoechea M","year":"2010","unstructured":"Goicoechea M, de Vinuesa SG, Verdalles U, et al.. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010, 5:1388-93. 10.2215\/CJN.01580210","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.131159","article-title":"Effect of urate-lowering therapies on renal disease progression in patients with hyperuricemia","volume":"41","author":"Levy GD","year":"2014","unstructured":"Levy GD, Rashid N, Niu F, Cheetham TC. Effect of urate-lowering therapies on renal disease progression in patients with hyperuricemia. J Rheumatol. 2014, 41:955-62. 10.3899\/jrheum.131159","journal-title":"J Rheumatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.4103\/0971-4065.114499","article-title":"Allopurinol for prevention of progression of kidney disease with hyperuricemia","volume":"23","author":"Pai BH","year":"2013","unstructured":"Pai BH, Swarnalatha G, Ram R, Dakshinamurty KV. Allopurinol for prevention of progression of kidney disease with hyperuricemia. Indian J Nephrol. 2013, 23:280-6. 10.4103\/0971-4065.114499","journal-title":"Indian J Nephrol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/8816478","article-title":"Left ventricular mass index in end-stage renal disease patients during hemodialysis and continuous ambulatory peritoneal dialysis","volume":"2023","author":"Nguyen NN","year":"2023","unstructured":"Nguyen NN, Van Duong P, Ngoc Mai TH, Vo NH, Luong DK, Ngo TH. Left ventricular mass index in end-stage renal disease patients during hemodialysis and continuous ambulatory peritoneal dialysis. Int J Clin Pract. 2023, 2023:8816478. 10.1155\/2023\/8816478","journal-title":"Int J Clin Pract"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-139-2-200307150-00013","article-title":"National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"139","author":"Levey AS","year":"2003","unstructured":"Levey AS, Coresh J, Balk E, et al.. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003, 139:137-47. 10.7326\/0003-4819-139-2-200307150-00013","journal-title":"Ann Intern Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2017.12.009","article-title":"Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: report of a scientific workshop organized by the National Kidney Foundation","volume":"71","author":"Johnson RJ","year":"2018","unstructured":"Johnson RJ, Bakris GL, Borghi C, et al.. Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: report of a scientific workshop organized by the National Kidney Foundation. Am J Kidney Dis. 2018, 71:851-65. 10.1053\/j.ajkd.2017.12.009","journal-title":"Am J Kidney Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.58490\/ctump.2023i64.1285","article-title":"Rate of hyperuricemia and some related factors in end-stage renal disease patients undergoing hemodialysis at Cau Mau general hospital","volume":"64","author":"Tran TTQ","year":"2023","unstructured":"Tran TTQ, Nguyen NN, Mai HNT. Rate of hyperuricemia and some related factors in end-stage renal disease patients undergoing hemodialysis at Cau Mau general hospital. CTUMP. 2023, 64:160-7. 10.58490\/ctump.2023i64.1285","journal-title":"CTUMP"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2015.30.2.162","article-title":"Diagnostic performance of body mass index using the Western Pacific Regional Office of World Health Organization reference standards for body fat percentage","volume":"30","author":"Yoon JL","year":"2015","unstructured":"Yoon JL, Cho JJ, Park KM, Noh HM, Park YS. Diagnostic performance of body mass index using the Western Pacific Regional Office of World Health Organization reference standards for body fat percentage. J Korean Med Sci. 2015, 30:162-6. 10.3346\/jkms.2015.30.2.162","journal-title":"J Korean Med Sci"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.51298\/vmj.v523i1.4428","article-title":"Assessment of the serum acid uric concentration in patients with chronic kidney disease without replacement therapy at Thanh Hoa province general hospital","volume":"523","author":"Le HN","year":"2023","unstructured":"Le HN, Do GT, Dang TVH, Nghiem TD, D\u01b0\u01a1ng DH, Pham TLT. Assessment of the serum acid uric concentration in patients with chronic kidney disease without replacement therapy at Thanh Hoa province general hospital. Vietnam Med J. 2023, 523:134-9. 10.51298\/vmj.v523i1.4428","journal-title":"Vietnam Med J"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.51298\/vmj.v509i2.1837","article-title":"Blood uric acid levels in patients with chronic kidney disease in Da Nang C hospital","volume":"509","author":"Huynh TNA","year":"2024","unstructured":"Huynh TNA, Le TT, Ho TTT, et al.. Blood uric acid levels in patients with chronic kidney disease in Da Nang C hospital. Vietnam Med J. 2024, 509:242-6. 10.51298\/vmj.v509i2.1837","journal-title":"Vietnam Med J"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1590\/s0066-782x2011005000011","article-title":"Association between uric acid and cardiovascular risk variables in a non-hospitalized population","volume":"96","author":"Barbosa MC","year":"2011","unstructured":"Barbosa MC, Brand\u00e3o AA, Pozzan R, et al.. Association between uric acid and cardiovascular risk variables in a non-hospitalized population. Arq Bras Cardiol. 2011, 96:212-8. 10.1590\/s0066-782x2011005000011","journal-title":"Arq Bras Cardiol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.1899-18","article-title":"Achievement of target serum uric acid levels and factors associated with therapeutic failure among Japanese men treated for hyperuricemia\/gout","volume":"58","author":"Katayama A","year":"2019","unstructured":"Katayama A, Yokokawa H, Fukuda H, Ono Y, Isonuma H, Hisaoka T, Naito T. Achievement of target serum uric acid levels and factors associated with therapeutic failure among Japanese men treated for hyperuricemia\/gout. Intern Med. 2019, 58:1225-31. 10.2169\/internalmedicine.1899-18","journal-title":"Intern Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/art.20761","article-title":"Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: the third national health and nutrition examination survey","volume":"52","author":"Choi HK","year":"2005","unstructured":"Choi HK, Liu S, Curhan G. Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: the third national health and nutrition examination survey. Arthritis Rheum. 2005, 52:283-9. 10.1002\/art.20761","journal-title":"Arthritis Rheum"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/nu12123835","article-title":"he association between purine-rich food intake and hyperuricemia: a cross-sectional study in Chinese adult residents","volume":"12","author":"Aihemaitijiang S","year":"2020","unstructured":"Aihemaitijiang S, Zhang Y, Zhang L, et al.. he association between purine-rich food intake and hyperuricemia: a cross-sectional study in Chinese adult residents. Nutrients. 2020, 12:3835. 10.3390\/nu12123835","journal-title":"Nutrients"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0170393","article-title":"Serum uric acid and progression of kidney disease: a longitudinal analysis and mini-review","volume":"12","author":"Tsai CW","year":"2017","unstructured":"Tsai CW, Lin SY, Kuo CC, Huang CC. Serum uric acid and progression of kidney disease: a longitudinal analysis and mini-review. PLoS One. 2017, 12:e0170393. 10.1371\/journal.pone.0170393","journal-title":"PLoS One"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph13070732","article-title":"The relation of moderate alcohol consumption to hyperuricemia in a rural general population","volume":"13","author":"Li Z","year":"2016","unstructured":"Li Z, Guo X, Liu Y, Chang Y, Sun Y, Zhu G, Abraham MR. The relation of moderate alcohol consumption to hyperuricemia in a rural general population. Int J Environ Res Public Health. 2016, 13:732. 10.3390\/ijerph13070732","journal-title":"Int J Environ Res Public Health"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e32835d951e","article-title":"Metabolic syndrome, diabetes, and hyperuricemia","volume":"25","author":"Li C","year":"2013","unstructured":"Li C, Hsieh MC, Chang SJ. Metabolic syndrome, diabetes, and hyperuricemia. Curr Opin Rheumatol. 2013, 25:210-6. 10.1097\/BOR.0b013e32835d951e","journal-title":"Curr Opin Rheumatol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2019.05.004","article-title":"Differences in the association between glycemia and uric acid levels in diabetic and non-diabetic populations","volume":"33","author":"Kuo KT","year":"2019","unstructured":"Kuo KT, Chang YF, Wu IH, Lu FH, Yang YC, Wu JS, Chang CJ. Differences in the association between glycemia and uric acid levels in diabetic and non-diabetic populations. J Diabet Complicat. 2019, 33:511-5. 10.1016\/j.jdiacomp.2019.05.004","journal-title":"J Diabet Complicat"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2017.01.055","article-title":"Management of gout and hyperuricemia in CKD","volume":"70","author":"Vargas-Santos AB","year":"2017","unstructured":"Vargas-Santos AB, Neogi T. Management of gout and hyperuricemia in CKD. Am J Kidney Dis. 2017, 70:422-39. 10.1053\/j.ajkd.2017.01.055","journal-title":"Am J Kidney Dis"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0000000000000699","article-title":"Recent evidence on the effect of urate-lowering treatment on the progression of kidney disease","volume":"30","author":"Tiku A","year":"2021","unstructured":"Tiku A, Johnson DW, Badve SV. Recent evidence on the effect of urate-lowering treatment on the progression of kidney disease. Curr Opin Nephrol Hypertens. 2021, 30:346-52. 10.1097\/MNH.0000000000000699","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2018.06.028","article-title":"Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial","volume":"72","author":"Kimura K","year":"2018","unstructured":"Kimura K, Hosoya T, Uchida S, et al.. Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial. Am J Kidney Dis. 2018, 72:798-810. 10.1053\/j.ajkd.2018.06.028","journal-title":"Am J Kidney Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/291953-the-impact-of-uric-acid-lowering-therapy-on-the-progression-of-non-dialysis-chronic-kidney-disease-a-prospective-cohort-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,29]],"date-time":"2024-09-29T12:17:49Z","timestamp":1727612269000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/291953-the-impact-of-uric-acid-lowering-therapy-on-the-progression-of-non-dialysis-chronic-kidney-disease-a-prospective-cohort-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,29]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.70435","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,29]]}}}